ArticleJCO precision oncology2017

Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors.

Anshuman Panda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.